EXOZYMES INC

eXoZymes Inc. tackles losses while advancing a synthetic‑biology platform, using strategic funding to sustain growth and aim for future profitability.

eXoZymes secures $2 million NIH grant to fast‑track rare cannabinoid production, advancing AI‑powered enzyme tech for future pharma breakthroughs.

eXoZymes Inc’s Nasdaq stock rebounds from a $7.08 low to nearly $9.88, reflecting strategic moves amid healthcare volatility—market cap $83.8M and future growth insights.

eXoZymes Inc is facing significant financial struggles, with a declining stock price and negative Price Earnings ratio, raising concerns about its business model and ability to turn around its fortunes.